Orchid Pharma reported Q2 FY 25 sales of INR 222.7 crores, with a cumulative half-year sales increase of 22% to INR 467.1 crores and a successful launch of their new drug ORBLICEF in India.
AI Assistant
Orchid Pharma Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.